Thomas Fabre’s Post

What do you see as the current challenges and opportunities across the industry……We ask some of the speakers, attendees and exhibitors of EUCROF24…… During the EUCROF24 Conference, we spoke with Alan Yeomans of Viedoc and member of the Conference Programme Committee. In this video, Alan discusses the challenges of conducting research, including issues related to quantity, timing, and cost. He also talks about how industry opportunities are evolving with each conference, highlighting how regulators across Europe are now more actively engaging with stakeholders and gathering valuable feedback on how the industry works. EUCROF25, taking place in Copenhagen from 2-4 February 2025, aims to further enrich the dialogue and cooperation across the spectrum of clinical research sectors, with sessions designed to reflect the current state of clinical research while also exploring the pressing challenges and exciting opportunities that lie ahead. Find out more and book your early bird place here: https://lnkd.in/e8bt2cqG Dr. Martine Dehlinger-Kremer, Simon Lee, Martin O'Kane, Sverre Bengtsson, Benedikt Van Nieuwenhove, Alexandre Malouvier, Antonio Torres, Nicole Bohrmann, Fiona Maini, Cristina Florescu Moraid, Alan Yeomans, Nira Garty #EUCROF #clinicalresearch #clinicaltrials #clinicaloperations #gcp #bigpharma #dct #EUCROF25

In 2023, the global CAGT market was estimated at nearly $23bn – but bringing life-changing therapies to patients quickly, safely, and successfully calls for a deep dive into the complex clinical and laboratory considerations impacting CAGT development. Hear what our experts have to say. https://bit.ly/3WFCH26 #CAGT #drugdevelopment #clinicalstudies

In 2023, the global CAGT market was estimated at nearly $23bn – but bringing life-changing therapies to patients quickly, safely, and successfully calls for a deep dive into the complex clinical and laboratory considerations impacting CAGT development. Hear what our experts have to say. https://bit.ly/3XVKzx4 #CAGT #drugdevelopment #clinicalstudies

In 2023, the global CAGT market was estimated at nearly $23bn – but bringing life-changing therapies to patients quickly, safely, and successfully calls for a deep dive into the complex clinical and laboratory considerations impacting CAGT development. Hear what our experts have to say. https://bit.ly/41xiYVe #CAGT #drugdevelopment #clinicalstudies

We are excited to share with you our ambitions for the next 4 years. Building on the achievements of the past strategic plan, and the decade since ECRIN has achieved its ERIC status, the new strategic plan is marks a consolidation phase for ECRIN. To meet our objectives we have built the strategic plan around five overarching goals to drive ECRIN’s activity for 2024-2027: 1) Ensure scientific excellence and public health relevance 2) Cultivate a thriving and empowered ECRIN community 3) Forging the path for future ECRIN activities 4) Consolidate and promote our visibility and awareness 5) Sustain engagement with the research infrastructure ecosystem Delve into our strategic plan today: https://lnkd.in/eAmEEcT3 CZECRIN, Infrastructure F-CRIN, GreCRIN, HNHRA, HRB National Clinical Trials Office (NCTO), ItaCRIN, KKSN, NorCRIN, PCTN, PtCRIN Portuguese Clinical Research Infrastructure Network, Spanish Clinical Research Network (SCReN), SLOVACRIN, Swiss Clinical Trial Organisation, ERIC Forum

In this interview, recorded at the 2024 DPHARM: Disruptive Innovations to Advance Clinical Research, Peyton Howell, MHA, Parexel, shares the organization's top priorities for the near-future, how she's maintained a patient-centric approach while innovating clinical trials, some of the top macro-factors impacting clinical research, and what she's gaining at the DPHARM 2024 meeting. Watch the full interview here: https://lnkd.in/gR2dSRAT #DPHARM2024 #clinicalresearch #patientcentricity

With more than 50 speakers .... more than 30 exhibitors ..... and a wide ranging programme .... there are now only 10 weeks to go until EUCROF25 .... Join us from February 2-4, 2025, in the vibrant city of Copenhagen, Denmark, for the 2025 European Clinical Research Conference (EUCROF25). EUCROF24 set new records, with attendance surpassing 325 professionals from over 170 organisations and more than 25 countries, making it the largest and most diverse EUCROF conference to date. EUCROF25 promises to be even bigger and better than the 2024 edition. With a unique blend of insightful keynote speakers and specialist breakout sessions, there is something on the programme for everyone involved in clinical research. To find out more about the speakers and programme visit here: https://lnkd.in/eEYsx8WT EUCROF25 Premier Sponsors: EvidentIQ, Medidata Solutions, Nubilaria - Your data specialists, Curewiki Dr. Martine Dehlinger-Kremer, Simon Lee, Martin O'Kane, Sverre Bengtsson, Benedikt Van Nieuwenhove, Alexandre Malouvier, Antonio Torres, Nicole Bohrmann, Cristina Florescu Moraid, Alan Yeomans, Nira Garty #EUCROF #clinicalresearch #clinicaltrials #clinicaloperations #gcp #bigpharma #dct #EUCROF25

In 2023, the global CAGT market was estimated at nearly $23bn – but bringing life-changing therapies to patients quickly, safely, and successfully calls for a deep dive into the complex clinical and laboratory considerations impacting CAGT development. Hear what our experts have to say. https://bit.ly/3R3g58A #CAGT #clinicaldevelopment

Excited to be speaking at the EUCROF25 in Copenhagen next year. It's great to see that clinical research disclosure 📚 and data transparency 🔐 are taking main stage and becoming more and more integrated into the end-to-end processes of drug discovery and development. In a field that's constantly evolving and improving, our Transparency & Disclosure team at Certara is leading the way and working with regulators, sponsors and technology vendors towards a pharmaceutical industry that is transparent, trustworthy and benefiting millions of patients worldwide. #ClinicalTransparency #DataPrivacy #ClinicalResearch

This past week was an incredible week at H1 for a few reasons: 1) We launched the industry’s first ever built AI-powered Site rescue functionality that leverages all of H1's data platform to recommend which HCPs and Sites can help hit your patient recruitment goals if one of your sites is not recruiting on time. 2) Our teams didn't stop there, we launched to every one of H1's clients that use our Clinical Suite information on patient Race and Ethnicity to promote representative clinical trials in the UK. 3) We attended Fierce Pharma's Clinical conference, Society for Clinical Research Sites (SCRS) in Florida, and DPHARM: Disruptive Innovations to Modernize Clinical Research to talk about these new innovations that our teams have built to continue to pioneer new innovations for the clinical trial industry! If you haven't seen what H1 is building come check it out! https://lnkd.in/ehrpyQYa